Clinical Report: Extended antiviral therapy may not improve long COVID
Overview
The RECOVER-VITAL trial, a randomized, double-blind, placebo-controlled study, found that nirmatrelvir–ritonavir treatment for up to 25 days did not significantly improve cognitive dysfunction, autonomic dysfunction, or exercise intolerance in long COVID patients compared to placebo. The study included 964 patients, with a median age of 49 years, 67% female, and 78% White, and showed no statistically significant differences in primary or secondary outcomes across treatment groups.
Background
Long COVID presents a significant public health challenge, with many patients experiencing persistent symptoms following SARS-CoV-2 infection. The RECOVER-VITAL trial aimed to evaluate the efficacy of nirmatrelvir–ritonavir, an antiviral therapy, in addressing long COVID symptoms.
Data Highlights
Outcome
25-Day Nirmatrelvir-Ritonavir
15-Day Nirmatrelvir-Ritonavir
Placebo
Cognitive Dysfunction Improvement
58%
53%
55%
Autonomic Dysfunction Improvement
62%
70%
70%
Exercise Phenotype Improvement
25%
34%
33%
Key Findings
Nirmatrelvir–ritonavir treatment for up to 25 days did not improve long COVID symptoms compared to placebo.
Among cognitive dysfunction patients, 58% improved with 25 days of treatment versus 55% with placebo.
For autonomic dysfunction, 62% improved with 25 days of treatment compared to 70% with placebo.
Only 25% of patients with exercise phenotype improved with the 25-day regimen compared to 33% with placebo.
No new safety signals were identified, with serious adverse events occurring in 4% of patients across treatment groups.
Subgroup analyses showed no differential treatment effects based on vaccination status, race, or sex.
Clinical Implications
The findings indicate that extended antiviral therapy with nirmatrelvir–ritonavir did not improve long COVID symptoms.
Conclusion
The RECOVER-VITAL trial results indicate that nirmatrelvir–ritonavir does not provide significant benefits for long COVID symptoms.
